RESUMEN
Continuous drug monitoring is a promising alternative to current therapeutic drug monitoring strategies and has a strong potential to reshape our understanding of pharmacokinetic variability and to improve individualised therapy.This review highlights recent advances in biosensing technologies that support continuous drug monitoring in real time.We focus primarily on aptamer-based biosensors,wearable and implantable devices.Emphasis is given to the approaches employed in constructing biosensors.We pay attention to sensors'biocompatibility,calibration performance,long-term characteristics stability and measurement quality.Last,we discuss the current challenges and issues to be addressed in continuous drug monitoring to make it a promising,future tool for individualised therapy.The ongoing efforts are expected to result in fully integrated implantable drug biosensing technology.Thus,we may anticipate an era of advanced healthcare in which wearable and implantable biochips will automatically adjust drug dosing in response to patient health conditions,thus enabling the management of diseases and enhancing individualised therapy.
RESUMEN
Objective To prepare the hydroxysafflor yellow A (HSY-A)enteric coating pellets,and investigate in vitro release and in vivo pharmacokinetic characteristics.Methods HSY-A enteric coating pellets were prepared by extrude-rounding and fluid bed technique.The micromeritic characteristics,the factors affecting the release properties of enteric coating pellets the release mechanism were explored,and the in vivo pharmacokinetic behaviors were also evaluated.Results The in vitro release behavior of HSY-A from enteric coating pellets could be described by Ritger-peppas equation,and fit diffusion mechanism,in vivo pharmacokinetic test confirmed the argument that pellets have good acid residence and enteric properties. Conclusion HSY-A enteric coating pellets have been successfully prepared and the expected release properties is achieved in the study.
RESUMEN
Objective To study the pharmacokinetics of puerarin and its phospholipid complex in Beagle dogs in vivo.Methods To determine the puerarin concentration in blood by HPLC,carry on the cross-experiments in the same group of dogs,and calculate the data using 3P97 pharmacokinetic program software.Results The concentration-time profiles of puerarin after ig puerarin and its phospholipid complex(equivalent to 52.5 mg/kg of puerarin) were shown to fit two-compartment open model with first-order absorption.Their AUC,C_(max),and t_(max) for puerarin were(10.91?4.83) mg?h/L,(3.00?1.13) mg/L,and(1.62?0.30) h,while for puerarin in phospholipid complex were(13.67?2.72) mg?h/L,(1.91?0.51) mg/L,and(2.38?1.27) h,respectively.Difference in AUC is significant.Conclusion(Phospholipid complex) formation can effectively enhance puerarin absorption in Beagle dogs in vivo.